se of Fluorescent dyes in detection of malignant node in breast cancer patients
Phase 1
- Conditions
- Health Condition 1: C50- Malignant neoplasm of breast
- Registration Number
- CTRI/2020/06/025772
- Lead Sponsor
- Department Of Surgical Disciplines
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All ladies with early breast cancer proven by histopathology
Exclusion Criteria
1.Ladies not giving consent
2.Palpable axillary lymph nodes
3.Patient with distant metastasis
4.Inflammatory carcinoma breast
5.Patients with prior surgery to breast or axilla, scaring in axilla due to burns, trauma
6.Patients with multicentric and multifocal tumors and with h/o previous radiotherapy and/ chemotherapy.
7.Pregnant and lactating mothers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of Sentinel Lymph node by Each dye in Breast Cancer PatientsTimepoint: Intraoperative
- Secondary Outcome Measures
Name Time Method 1. To compare the direct cost in two arms of therapy and to perform a cost effective analysis. <br/ ><br>2. To record the possible adverse effects occuring due to use of Indocyanine Green and FluoresceinTimepoint: 1 day